This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keirns, J.
Right arrow Articles by Alak, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keirns, J.
Right arrow Articles by Alak, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2007, p. 787-790, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.00673-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults{triangledown}

J. Keirns,* T. Sawamoto, M. Holum, D. Buell, W. Wisemandle, and A. Alak

Astellas Pharma US, Inc., Deerfield, Illinois 60015-2548

Received 1 June 2006/ Returned for modification 30 August 2006/ Accepted 10 November 2006

We assessed the pharmacokinetics and interactions of steady-state micafungin (Mycamine) or placebo with steady-state voriconazole in 35 volunteers. The 90% confidence intervals around the least-squares mean ratios for micafungin pharmacokinetic parameters and placebo-corrected voriconazole pharmacokinetic parameters were within the 80%-to-125% limits, indicating an absence of drug interaction.

* Corresponding author. Mailing address: Astellas Pharma US, Inc., 3 Parkway North, Deerfield, IL 60015. Phone: (847) 317-8815. Fax: (847) 317-5983. E-mail: jim.keirns{at}us.astellas.com.

{triangledown} Published ahead of print on 20 November 2006.

Antimicrobial Agents and Chemotherapy, February 2007, p. 787-790, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.00673-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Nicasio, A. M., Tessier, P. R., Nicolau, D. P., Knauft, R. F., Russomanno, J., Shore, E., Kuti, J. L. (2009). Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers. Antimicrob. Agents Chemother. 53: 1218-1220 [Abstract] [Full Text]  
  • Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., Bohrmueller, J. (2008). In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 3497-3503 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»